Incyte Corporation (NASDAQ:INCY) saw a downside of -0.26% to close Friday at $64.04 after subtracting -$0.17 on the day. The 5-day average trading volume is 1,359,300 shares of the company’s common stock. It has gained $66.15 in the past week and touched a new high 1 time within the past 5 days. An average of 1,471,525 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,882,978.
INCY’s 1-month performance is 0.05% or $2.36 on its low of $62.03 reached on 07/19/23. The company’s shares have touched a 52-week low of $60.56 and high of $86.29, with the stock’s rally to the 52-week high happening on 01/26/23. YTD, INCY has lost -20.27% or -$16.28 and has reached a new high 10 times. However, the current price is down -25.79% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
INCY stock investors last saw insider trading activity on Aug 01.Stein Steven H (EVP & Chief Medical Officer) most recently sold 21,511 shares at $63.28 per share on Aug 01. This transaction cost the insider $1,361,216. EVP & General Counsel, Pasquale Maria E, sold 802 shares at a price of $84.06 on Jan 31. Then, on Jan 30, EVP & General Counsel Pasquale Maria E sold 60,024 shares at a price of $84.74 per share. This transaction amounted to $5,086,569.
Valuation Metrics
INCY stock has a beta of 0.68. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.10 while the price-to-book (PB) in the most recent quarter is 3.02, with the price to cash flow ratio at 20.19.
Incyte Corporation’s quick ratio for the period ended June 29 was 3.80, with the current ratio over the same period at 3.80. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.01, while the total debt to equity was 0.01. In terms of profitability, the gross margin trailing 12 months is 93.80%. The trailing 12-month EBITDA margin is 19.66% while for the period ending June 29, Incyte Corporation’s operating margin was 12.20%. The firm’s gross profit as reported stood at $3.19 billion against revenue of $3.39 billion.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 20.69% to $203.55 million, while revenue of $21.7 million was 89.34% off the previous quarter. Analysts expected INCY to announce $0.83 per share in earnings in its latest quarter, but it posted $0.99, representing a 19.30% surprise. EBITDA for the quarter stood at more than $214.08 million. INCY stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.47 billion, with total debt at $39.74 million. Shareholders hold equity totaling $224.09 million.
Let’s look briefly at Incyte Corporation (INCY) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 45.32% to suggest the stock is trending Neutral, with historical volatility in this time period at 12.27%.
The stock’s 5-day moving average is $64.73, reflecting a -2.87% or -$1.89 change from its current price. INCY is currently trading -0.17% above its 20-day SMA, -9.56% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +4.32% and SMA200 by-13.86%.
Stochastic %K and %D was 50.22% and 60.11% and the average true range (ATR) pointed at 1.16. The RSI (14) points at 49.27%, while the 14-day stochastic is at 43.45% with the period’s ATR at 1.19. The stock’s 9-day MACD Oscillator is pointing at -0.68 and -0.52 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Incyte Corporation (NASDAQ: INCY), Citigroup launched coverage with a Buy rating. Analysts offering their rating for INCY stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate INCY as a “sell,”, while 11 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 9 have offered a “buy” rating.
What is INCY’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $65.00 and a high of $114.00, with their median price target at $82.00. Looking at these predictions, the average price target given by analysts is for Incyte Corporation (INCY) stock is $82.52.
